THE MCMANUS GROUP
On the record as: lobbying firm, lobbyists' giving (LD-203).
—
from its PAC to 0 members, 2021 on
—
on 0 lobbying reports as a client
37
clients as a lobbying firm ($28.1M reported income)
$421K
its lobbyists report giving 67 members (LD-203)
What its lobbyists report giving members (LD-203)
The members it gave most, colored by party.
Kevin McCarthy
R-CA
$50K
Mike Johnson
R-LA
$34K
Tom Emmer
R-MN
$25K
$25K
Vern Buchanan
R-FL
$22K
Jason Smith
R-MO
$19K
Michelle Steel
R-CA
$15K
$11K
$9,500
Neal P. Dunn
R-FL
$9,250
Markwayne Mullin
R-OK
$8,800
Devin Nunes
R-CA
$8,500
Brett Guthrie
R-KY
$8,200
$7,400
David Schweikert
R-AZ
$7,000
Mike Carey
R-OH
$6,500
$6,500
John Joyce
R-PA
$6,250
Larry Bucshon
R-IN
$6,200
Richard Hudson
R-NC
$6,000
All 60 members
Its clients, as a lobbying firm (37)
$1.3M
$1.2M
$1.1M
$1.1M
$1.0M
$990K
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP)
$930K
The top 37
| Client | Reports | Income reported |
|---|---|---|
| LARGE UROLOGY GROUP PRACTICE ASSOCIATION | 23 | $2.1M |
| INFUSION PROVIDERS ALLIANCE | 23 | $1.9M |
| NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) | 23 | $1.4M |
| AMBULATORY SURGERY CENTER ASSOCIATION | 23 | $1.4M |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 23 | $1.3M |
| GILEAD SCIENCES, INC. | 23 | $1.3M |
| AMGEN | 23 | $1.3M |
| GRAIL, INC. | 23 | $1.2M |
| WEX HEALTH | 23 | $1.1M |
| GENENTECH | 23 | $1.1M |
| DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. | 17 | $1.1M |
| ALNYLAM PHARMACEUTICALS | 19 | $1.0M |
| EMD SERONO, INC. | 20 | $1.0M |
| ZIMMER BIOMET | 23 | $990K |
| PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) | 19 | $930K |
| AMERICAN OCCUPATIONAL THERAPY ASSOCIATION | 23 | $920K |
| DENDREON PHARMACEUTICALS LLC | 23 | $850K |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 23 | $790K |
| ORCHARD THERAPEUTICS NORTH AMERICA | 12 | $750K |
| HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) | 12 | $720K |
| VIVEX BIOLOGICS | 11 | $520K |
| AVADEL PHARMACEUTICALS | 9 | $440K |
| BRISTOL-MYERS SQUIBB | 5 | $400K |
| INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) | 9 | $390K |
| ARDELYX | 7 | $380K |
| ACESSO BIOLOGICS | 7 | $370K |
| ALKERMES, INC. | 8 | $355K |
| PTC THERAPEUTICS INC. | 12 | $350K |
| ROCHE DIAGNOSTICS | 9 | $330K |
| BIOWOUND SOLUTIONS | 7 | $320K |
| FULCRUM THERAPEUTICS | 6 | $270K |
| VIALASE INC. | 4 | $200K |
| OWLET | 6 | $180K |
| SIGHT SCIENCES | 4 | $160K |
| ROYAL BIOLOGICS | 3 | $110K |
| MEDICARE ALLIANCE FOR BENEFICIARY ACCESS (MABA) | 2 | $80K |
| VENTURE MEDICAL | 3 | $80K |